Susquehanna International Group, LLP Oncocyte Corp Transaction History

Susquehanna International Group, LLP

$560 Billion
Q3 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 16, 2023	SELL	$0.2 - $0.49 $6,163 - $15,099	-30,816 Reduced 46.98%	34,776 $12,000
Q4 2022 Feb 14, 2023	BUY	$0.25 - $15.6 $16,398 - $1.02 Million	65,592 New	65,592 $20,000
Q2 2022 Aug 15, 2022	BUY	$0.86 - $1.53 $108,959 - $193,846	126,697 Added 663.09%	145,804 $131,000
Q4 2021 Feb 14, 2022	SELL	$2.04 - $3.59 $9,008 - $15,853	-4,416 Reduced 18.77%	19,107 $41,000
Q3 2021 Nov 15, 2021	SELL	$3.53 - $5.89 $135,050 - $225,339	-38,258 Reduced 61.93%	23,523 $84,000
Q1 2021 May 17, 2021	BUY	$2.39 - $6.5 $85,659 - $232,966	35,841 Added 138.17%	61,781 $321,000
Q4 2020 Feb 16, 2021	SELL	$1.38 - $2.63 $49,606 - $94,540	-35,947 Reduced 58.08%	25,940 $62,000
Q3 2020 Nov 16, 2020	BUY	$1.2 - $1.89 $74,264 - $116,966	61,887 New	61,887 $86,000
Q2 2020 Aug 14, 2020	SELL	$1.91 - $3.45 $34,238 - $61,844	-17,926 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$1.76 - $3.02 $9,479 - $16,265	-5,386 Reduced 23.1%	17,926 $44,000
Q4 2019 Feb 14, 2020	SELL	$1.51 - $2.27 $27,087 - $40,721	-17,939 Reduced 43.49%	23,312 $52,000
Q3 2019 Nov 14, 2019	SELL	$1.59 - $2.51 $18,383 - $29,020	-11,562 Reduced 21.89%	41,251 $87,000
Q2 2019 Aug 16, 2019	BUY	$2.49 - $5.45 $3,979 - $8,709	1,598 Added 3.12%	52,813 $132,000
Q2 2019 Aug 14, 2019	BUY	$2.49 - $5.45 $55,412 - $121,284	22,254 Added 76.84%	51,215 $128,000
Q1 2019 May 15, 2019	BUY	$1.47 - $5.91 $42,572 - $171,159	28,961 New	28,961 $114,000
Q1 2018 May 15, 2018	SELL	$1.25 - $4.6 $12,982 - $47,775	-10,386 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$3.9 - $7.4 $40,505 - $76,856	10,386	10,386 $48,000

Others Institutions Holding OCX

# of Institutions

Shares Held

411K

Call Options Held

Put Options Held

View Full List

About Oncocyte Corp

Ticker OCX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,609,000
Market Cap $260M
Description
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay....

More about OCX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account